Rapid Micro Biosystems, Inc., a life sciences technology company, provides products for the detection of microbial contamination in the manufacture of pharmaceutical, medical devices, and personal care products in North America, Europe, and Asia. The company offers Growth Direct platform, which includes Growth Direct system, proprietary consumables, lab information management system connection software, and comprehensive customer support and validation services. Its platform automates and modernizes the manual microbial quality control (MQC) testing workflows for therapeutic modalities, such as biologics, vaccines, cell and gene therapies, and sterile injectables. The company also provides installation and verification, technical training, and support services. Its solutions are used in environmental monitoring, water testing, bioburden, and sterility release testing applications. The company was formerly known as Genomic Profiling Systems, Inc. and changed its name to Rapid Micro Biosystems, Inc. in January 2007. Rapid Micro Biosystems, Inc. was incorporated in 2006 and is headquartered in Lowell, Massachusetts.
P/E ratio for Rapid Micro Biosystems, Inc. (RPID)
P/E ratio as of 2023: -0.61
According to Rapid Micro Biosystems, Inc.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -0.61. At the end of 2022 the company had a P/E ratio of -0.79.
P/E ratio history for Rapid Micro Biosystems, Inc. from 2019 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | -0.61 |
| 2022 | -0.79 |
| 2021 | -6.00 |
| 2020 | -22.32 |
| 2019 | -40.09 |